<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>55(2)</volume><submitter>Hilliard JJ</submitter><pubmed_abstract>Doripenem is a carbapenem with potent broad-spectrum activity against Gram-negative pathogens, including antibiotic-resistant Enterobacteriaceae. As the incidence of extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli is increasing, it was of interest to examine the in vivo comparative efficacy of doripenem, imipenem, and meropenem against a Klebsiella pneumoniae isolate expressing the TEM-26 ESBL enzyme. In a murine lethal lower respiratory infection model, doripenem reduced the Klebsiella lung burden by 2 log(10) CFU/g lung tissue over the first 48 h of the infection. Treatment of mice with meropenem or imipenem yielded reductions of approximately 1.5 log(10) CFU/g during this time period. Seven days postinfection, Klebsiella titers in the lungs of treated mice decreased</pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pagination>836-44</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3028822</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.</pubmed_title><pmcid>PMC3028822</pmcid><pubmed_authors>Bunting RA</pubmed_authors><pubmed_authors>Barron A</pubmed_authors><pubmed_authors>Hall L</pubmed_authors><pubmed_authors>Fernandez J</pubmed_authors><pubmed_authors>Ward CK</pubmed_authors><pubmed_authors>Flamm RK</pubmed_authors><pubmed_authors>Hilliard JJ</pubmed_authors><pubmed_authors>Abbanat D</pubmed_authors><pubmed_authors>Melton JL</pubmed_authors><pubmed_authors>Lynch AS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.</name><description>Doripenem is a carbapenem with potent broad-spectrum activity against Gram-negative pathogens, including antibiotic-resistant Enterobacteriaceae. As the incidence of extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli is increasing, it was of interest to examine the in vivo comparative efficacy of doripenem, imipenem, and meropenem against a Klebsiella pneumoniae isolate expressing the TEM-26 ESBL enzyme. In a murine lethal lower respiratory infection model, doripenem reduced the Klebsiella lung burden by 2 log(10) CFU/g lung tissue over the first 48 h of the infection. Treatment of mice with meropenem or imipenem yielded reductions of approximately 1.5 log(10) CFU/g during this time period. Seven days postinfection, Klebsiella titers in the lungs of treated mice decreased</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Feb</publication><modification>2025-04-05T00:26:52.311Z</modification><creation>2019-03-27T00:38:27Z</creation></dates><accession>S-EPMC3028822</accession><cross_references><pubmed>21135187</pubmed><doi>10.1128/AAC.00670-10</doi><doi>10.1128/aac.00670-10</doi></cross_references></HashMap>